

  <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    
    <div class="region region-content">
    <div data-drupal-messages-fallback class="hidden"></div>
  <div class="layout layout--onecol">
    <div  class="layout__region layout__region--content">
      <div data-block-plugin-id="extra_field_block:node:page:content_moderation_control">
  
    
      
  </div>
<div data-block-plugin-id="field_block:node:page:body">
  
    
      
  <div class="page page-0 full" style="width:1300px;" id="overview"><div class="slider-container full"><ul class="slider full"><li class="slide slide-0 full"><div class="ten24-center-only"><div class="row"><div class="slide-left"><h1 class="baby-blue">Welcome to the Otsuka DoseView&nbsp;<br>Calculator for atypical long-acting&nbsp;<br>injectable (aLAI) antipsychotics</h1><p class="white">This tool provides a window to pricing and dosing information for the currently&nbsp;<br>available aLAI antipsychotic products. You may quickly compare your plan's dose&nbsp;<br>mix against the nation, as well as calculate weighted average doses and weighted&nbsp;<br>average WAC<sup>*</sup> for these aLAI therapies, based on information you provide.</p><p class="white" style="font-size:12px;line-height:13px;margin-top:325px;">aLAI = atypical long-acting injectable&nbsp;<br><br>Data source: IQVIA NPA Portal through December 2023.&nbsp;<br><br>* Wholesale Acquisition Cost is Otsuka's price to its wholesalers/distributors without regard to customary prompt&nbsp;<br>&nbsp;&nbsp; pay discounts, bona fide service fees, credits, rebates, chargebacks or other concessions. It is a list price.</p></div><div class="slide-indication"><p><span class="uppercase bold blue">INDICATIONS</span></p><p class="black">ABILIFY ASIMTUFII<sup>®</sup> (aripiprazole) is an atypical antipsychotic indicated for:</p><ul style="margin-bottom:0px;"><li style="list-style-type:disc;">Treatment of schizophrenia in adults</li><li style="list-style-type:disc;">Maintenance monotherapy treatment of bipolar I disorder in adults</li></ul><p>&nbsp;</p><p class="black">ABILIFY MAINTENA<sup>®</sup> (aripiprazole) is an atypical antipsychotic indicated for:</p><ul style="margin-bottom:0px;"><li style="list-style-type:disc;">Treatment of schizophrenia in adults</li><li style="list-style-type:disc;">Maintenance monotherapy treatment of bipolar I disorder in adults</li></ul><p>&nbsp;</p><p class="bold blue uppercase">IMPORTANT SAFETY INFORMATION</p><p class="bold blue uppercase">Warning: Increased mortality in elderly patients with dementia-related psychosis</p><p class="bold">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death (1.6 to 1.7 times) compared to placebo-treated patients. ABILIFY ASIMTUFII and ABILIFY MAINTENA are not approved for the treatment of patients with dementia-related psychosis.</p><p>&nbsp;</p><p>Please see <a class="uppercase underlined grey" href="#isi">IMPORTANT SAFETY INFORMATION</a> below</p></div></div></div></li><li class="slide slide-1 full"><div class="ten24"><div class="row"><div class="slide-left"><h1 class="capitalized blue">For Formulary Decision-Makers</h1><p class="grey med-small">This presentation contains health care economic information (HCEI) that is intended for delivery&nbsp;<br>to payors, formulary committees, or similar entities responsible for reviewing product information&nbsp;<br>for the purposes of determining inclusion on the formularies of payors and other similar&nbsp;<br>organizations, per FDAMA 114 as amended by the 21st Century Cures Act, Section 3037.</p><p class="grey med-small">This information is not intended to make comparisons about product efficacy, safety, or dosing.</p><p class="grey med-small">The information presented herein is intended to provide estimated costs based economic&nbsp;<br>modeling and/or other data sources such as administrative claims data. Estimated costs are not&nbsp;<br>guaranteed and your real world experiences may differ.</p><h1 class="blue" style="margin-top:20px;">Your privacy is important</h1><p class="grey med-small">Otsuka America Pharmaceutical, Inc., (OAPI) is committed to protecting your privacy.&nbsp;<br>We recognize the right to keep your pharmacy utilization data private and do not&nbsp;<br>capture any of your health plan information.&nbsp;<br><br>For more information, see our <a class="grey capitalized underlined" href="http://www.otsuka-us.com/Pages/PrivacyPolicy_OAPI.aspx" target="_blank">Privacy Policy</a>.</p><p class="grey" style="font-size:10px;line-height:15px;width:1050px;">THIS TOOL IS PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS&nbsp;<br>FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. OTSUKA AMERICA PHARMACEUTICAL, INC. (OAPI) ASSUMES NO RESPONSIBILITY FOR ERRORS OR OMISSIONS IN THIS TOOL OR OTHER&nbsp;<br>DOCUMENTS OR DATA WHICH ARE USED OR REFERENCED BY OR LINKED TO THIS TOOL. IN NO EVENT SHALL OAPI OR ITS AFFILIATES BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL,&nbsp;<br>CONSEQUENTIAL, OR PUNITIVE DAMAGES OF ANY KIND, OR ANY DAMAGES WHATSOEVER, INCLUDING, WITHOUT LIMITATION, THOSE RESULTING FROM LOSS OF USE, DATA OR PROFITS, WHETHER&nbsp;<br>OR NOT ADVISED OF THE POSSIBILITY OF DAMAGE, AND ON ANY THEORY OF LIABILITY, ARISING OUT OF OR IN CONNECTION WITH THE USE OR PERFORMANCE OF THIS TOOL. THIS TOOL MAY&nbsp;<br>INCLUDE TECHNICAL OR OTHER INACCURACIES OR TYPOGRAPHICAL ERRORS. CHANGES OR UPDATES MAY BE PERIODICALLY MADE TO THE INFORMATION HEREIN.</p></div><div class="slide-right"><img src="/sites/g/files/qhldwo10681/files/lock_0.png" data-entity-uuid data-entity-type alt></div></div></div></li><li class="slide slide-2 full"><div class="ten24"><h1 class="full-width centered white">Methodology</h1><p class="full-width centered white">This calculator provides a comparison of atypical long-acting injectable (aLAI)&nbsp;<br>antipsychotics, using total prescriptions (TRx) across 3 measures:</p><p class="full-width centered white">This information is for your organization's use only. it is not intended to make&nbsp;<br>comparisons about product efficacy, safety, or dosing. Pricing is subject to change.</p><div class="row" style="margin-left:auto;margin-right:auto;width:1024px;"><div class="col-md-4 centered"><img src="/sites/g/files/qhldwo10681/files/dose-mix_0.png" data-entity-uuid data-entity-type alt><h2 class="full-width centered bold white">Dose Mix</h2></div><div class="col-md-4 centered"><img src="/sites/g/files/qhldwo10681/files/wad_0.png" data-entity-uuid data-entity-type alt><h2 class="full-width centered bold white">Weighted&nbsp;<br>Average Dose</h2></div><div class="col-md-4 centered"><img src="/sites/g/files/qhldwo10681/files/wac_0.png" data-entity-uuid data-entity-type alt><h2 class="full-width centered bold white">Weighted Wholesale&nbsp;<br>Acquisition Cost (WAC)</h2><p><button class="button blue-button" rel-overlay="/pages/content/overlays/methodology-overlay">Learn More</button></p></div></div></div></li><li class="slide slide-3 full"><div style="margin-left:auto !important;margin-right:auto !important;position:relative;top:-25px;width:1300px !important;"><h1 class="blue">WAC<sup>*</sup> Prices for aLAIs Vary by Dosage<sup>1-11</sup></h1><div class="row"><div class="col-md-6"><ul class="wac-dose wac-dose-1" style="margin-left:60px;"><li>Product Dosage <span>WAC per Dose<sup>†</sup></span></li></ul><p class="mice">WAC price as of <span class="acc-mn">01</span>/<span class="acc-d">1</span>/<span class="acc-y">2022</span>.&nbsp;<br>Products do not necessarily have equivalent indications.&nbsp;<br>IQVIA NPA data is updated quarterly. Redbook WAC data is subject to change.</p></div><div class="col-md-6"><ul class="wac-dose wac-dose-2" style="margin-right:70px;"><li>Product Dosage <span>WAC per Dose</span></li></ul><p class="mice mice-right">*Wholesale Acquisition Cost is Otsuka’s price to its wholesalers/distributors without regard to customary prompt pay discounts,&nbsp;<br>bona fide service fees, credits, rebates, chargebacks, or other concessions. It is a list price.&nbsp;<br><sup>†</sup>Redbook data as of <span class="acc-mn">01</span>/<span class="acc-d">1</span>/<span class="acc-y">2022</span>.&nbsp;<br>Trademarks are property of their respective owners.&nbsp;<br><sup>‡</sup>There is minimal volume utilization of the ZYPREXA 150 mg dose, and therefore this dose is not included</p></div></div><div class="row" style="display:flow-root;margin-bottom:-21px;"><div class="col-md-6"><h4 class="blue bold">Dose mix drives health plan cost for each aLAI antipsychotic. These variations can impact the cost to your organization. View a national benchmark for 12 months of aLAIs.</h4></div><div class="col-md-6"><button class="button blue-button" style="margin-bottom:2px;">View National Benchmark Data</button></div><div class="col-md-6 underline">&nbsp;</div></div><hr style="margin-bottom:2px;margin-top:0px;width:515px;"><p class="mice source-links" style="font-size:6pt !important;">&nbsp;</p></div></li><li class="slide slide-4 centered full"><div class="ten24"><h1 class="full-width white">See how variations in dose mix and&nbsp;<br>WAC price may impact your aLAI expenditures</h1><p class="full-width white">This tool demonstrates the impact of dose mix and WAC prices on your organization and provides a means for comparing these variables across all aLAI antipsychotics.</p><p><button class="button blue-button">Start the Calculator</button></p></div></li></ul><div class="full slider-controls-container">&nbsp;</div></div><div class="isi" id="isi">&nbsp;</div><div class="footer ten24">&nbsp;</div></div>

  </div>
<div data-block-plugin-id="extra_field_block:node:page:links">
  
    
      
  </div>
<div data-block-plugin-id="field_block:node:page:field_meta_tags">
  
    
      
  </div>

    </div>
  </div>


  </div>
  

  </div>